Skip Navigation


Rheumatology Advance Access originally published online on August 17, 2004
Rheumatology 2004 43(12):1476-1479; doi:10.1093/rheumatology/keh369
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
43/12/1476    most recent
keh369v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hulkkonen, J.
Right arrow Articles by Lehtimäki, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hulkkonen, J.
Right arrow Articles by Lehtimäki, T.
Related Collections
Right arrow Immunogenetics
Right arrow Sjogren's Syndrome
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 43 No. 12 © British Society for Rheumatology 2004; all rights reserved

PAPER

Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjögren's syndrome

J. Hulkkonen, M. Pertovaara1, J. Antonen1, A. Pasternack1, M. Hurme1, P. Pöllänen and T. Lehtimäki1

University of Tampere Medical School and 1 Tampere University Hospital, Tampere, Finland.

Correspondence to: J. Hulkkonen, Department of Microbiology and Immunology, Medical School, FIN-33014, University of Tampere, Finland. E-mail: bljahu{at}uta.fi

Objectives. To determine whether plasma matrix metalloproteinase 9 (MMP-9) and MMP9 (–1562C->T) polymorphism have an effect on the disease phenotype in primary Sjögren's syndrome (pSS).

Methods. Plasma MMP-9 concentrations and polymorphism of the MMP9 gene were analysed in 66 patients with pSS. These data were studied in relation to the clinical data of the patients. The genetic data of patients were compared with the data of 66 healthy subjects.

Results. Plasma MMP-9 was higher in patients with definite pSS than in patients with possible pSS. This association was principally caused by higher plasma MMP-9 in patients with a positive Schirmer test and keratoconjunctivitis sicca. pSS patients with purpura, SS-A autoantibodies and RF had significantly lower plasma MMP-9 than patients without these characteristics. The overall MMP9 (–1562C->T) allele frequencies were similar in patients and control subjects. The frequency of the allele T was higher in patients without Raynaud's phenomenon than in the control group.

Conclusions. MMP9 (–1562C->T) could not be used for risk assessment in pSS. The presence of the rarer allele T may decrease the risk of Raynaud's phenomenon in pSS. High plasma MMP-9 is indicative of definite pSS but may paradoxically have a preventive effect on the eruption of purpura and on the development of autoantibody reaction in pSS.

KEY WORDS: Polymorphism, Sjögren's syndrome, Gene, Matrix metalloproteinase, Gelatinase B, Plasma, Risk, Raynaud's phenomenon, Purpura


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.